Back to top
more

Novartis (NVS)

(Delayed Data from NYSE)

$113.50 USD

113.50
2,006,337

-4.23 (-3.59%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $114.63 +1.13 (1.00%) 6:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (90 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Ophthotech (OPHT) Q4 Loss Wider than Expected, Sales Miss

by Zacks Equity Research

Ophthotech Corporation (OPHT) reported fourth-quarter 2016 loss of $1.86 per share, wider than both the Zacks Consensus Estimate of a loss of $1.64 and the year-ago loss of $1.02.

    Zacks Equity Research

    Medicines Company (MDCO) Q4 Loss Narrower than Expected

    by Zacks Equity Research

    The Medicines (MDCO) reported a loss of $1.29 per share (including the impact of share-based compensation expenses) in the fourth quarter of 2016, narrower than Zacks Consensus Estimate of a loss of $1.43.

      Zacks Equity Research

      Conatus Pharmaceuticals (CNAT) Q4 Earnings: What's in Store?

      by Zacks Equity Research

      Conatus Pharmaceuticals Inc. (CNAT) is expected to report fourth-quarter 2016 results next month.

        Zacks Equity Research

        Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates

        by Zacks Equity Research

        Ligand Pharmaceuticals Incorporated (LGND) reported fourth-quarter 2016 earnings of 50 cents per share (including the impact of stock-based compensation expense), down 11.1% from the year-ago figure.

          Arpita Dutt headshot

          Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback

          by Arpita Dutt

          Merck's (MRK) news represents the latest setback in the pharma and biotech sector's quest to find a treatment for Alzheimer's.

            Zacks Equity Research

            Ligand (LGND) Q4 Earnings: Will the Stock Pull a Surprise?

            by Zacks Equity Research

            Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report fourth-quarter 2016 results on Feb 23, after the market closes.

              Zacks Equity Research

              Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook

              by Zacks Equity Research

              Incyte Corporation (INCY) reported fourth-quarter earnings of 15 cents beating the Zacks Consensus Estimate of 14 cents.

                Zacks Equity Research

                Teva (TEVA) Tops on Q4 Earnings, Maintains 2017 Guidance

                by Zacks Equity Research

                Teva Pharmaceutical Industries Ltd. (TEVA) reported fourth-quarter 2016 earnings of $1.34 per share (including equity compensation expenses), which beat the Zacks Consensus Estimate of $1.28.

                  Zacks Equity Research

                  Model N (MODN) Q1 Loss Narrower than Expected, Guides Well

                  by Zacks Equity Research

                  Model N, Inc. (MODN) reported a loss (excluding stock based compensation) of 21 cents per share in first-quarter 2017, which was narrower than the Zacks Consensus Estimate.

                    Zacks Equity Research

                    Teva: Vigodman Steps Down, Peterburg Hired as Interim CEO

                    by Zacks Equity Research

                    Teva Pharmaceutical Industries Ltd. (TEVA) recently announced that its present chief executive officer (CEO), Erez Vigodman, is stepping down.

                      Zacks Equity Research

                      Amgen (AMGN) Q4 Earnings Top; Repatha Positive in CV Study

                      by Zacks Equity Research

                      Amgen Inc. (AMGN) reported fourth-quarter 2016 earnings of $2.89 per share, beating the Zacks Consensus Estimate of $2.77 by 4.3% .

                        Zacks Equity Research

                        Novartis (NVS) Votubia Gets EU Approval for Label Expansion

                        by Zacks Equity Research

                        Novartis (NVS) wins EU approval for label expansion of Votubia in refractory partial-onset seizures in patients with tuberous sclerosis complex.

                          Zacks Equity Research

                          GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?

                          by Zacks Equity Research

                          GlaxoSmithKline plc (GSK) is scheduled to report fourth-quarter 2016 and full-year results on Feb 8. Last quarter, the company delivered a positive earnings surprise of 7.79%.

                            Zacks Equity Research

                            Momenta Says District of Delaware Invalidates Teva's MS Drug

                            by Zacks Equity Research

                            Shares of Momenta Pharmaceuticals, Inc. (MNTA) shot up 25.2% after Mylan N.V. (MYL) announced that the United States District Court for the District of Delaware has issued a decision in favor of the latter .

                              Arpita Dutt headshot

                              Drug Stocks Rally on Trump Meet with Pharma Bigwigs

                              by Arpita Dutt

                              Pharma and biotech stocks were up as President Trump discussed a speedier drug approval process, lower regulations and corporate tax reforms.

                                Madeleine Johnson headshot

                                Stock Market Roundup Jan. 31: Nasdaq Rebounds Amid Trump Biotech Meeting

                                by Madeleine Johnson

                                Following the trend set yesterday, U.S. stocks closed mostly lower on Tuesday but still managed to record monthly gains. Investors continue to weigh the latest policies from the Trump Administration as well as companies' results from the current earnings season.

                                  Ryan McQueeney headshot

                                  Biotech Stocks Gain on Latest Trump Drug Price Statements

                                  by Ryan McQueeney

                                  President Trump continues to double down on his campaign promises, and his latest statements regarding drug prices and regulation have sent biotech stocks higher on Tuesday.

                                    Zacks Equity Research

                                    Incyte and Calithera Enter into Deal for Oncology Candidate

                                    by Zacks Equity Research

                                    Incyte Corporation (INCY) and Calithera Biosciences, Inc. (CALA) entered into a global collaboration and license agreement for research, development and commercialization of Calithera's CB-1158 in hematology and oncology.

                                      Zacks Equity Research

                                      Amgen Wins Favorable CHMP Opinion for Humira Biosimilar

                                      by Zacks Equity Research

                                      Amgen (AMGN) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion on the company's marketing authorization application (MAA) for ABP 501.

                                        Zacks Equity Research

                                        Lilly's Elanco Unit & Aratana Launch Veterinary Pain Drug

                                        by Zacks Equity Research

                                        Eli Lilly and Company's (LLY) animal health subsidiary, Elanco and partner Aratana Therapeutics, Inc. (PETX) together announced the availability of Galliprant for the management of pain and inflammation associated with canine osteoarthritis (OA).

                                          Zacks Equity Research

                                          Novartis (NVS) Beats Q4 Earnings, Might Spin-Off Alcon

                                          by Zacks Equity Research

                                          Novartis' (NVS) fourth-quarter 2016 results were mixed with the company beating earnings estimates but missing on revenues. The company has been facing challenging conditions for the past few quarters.

                                            Zacks Equity Research

                                            Novartis (NVS) Q4 Earnings: Stock Likely to Disappoint?

                                            by Zacks Equity Research

                                            Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report fourth-quarter and full year 2016 results on Jan 25.

                                              Zacks Equity Research

                                              Novartis to Conduct Trial on Obese, Type II Diabetes Patients

                                              by Zacks Equity Research

                                              In a recent announcement, MorphoSys AG mentioned that its partner Swiss major Novartis AG (NVS) will conduct a phase II clinical trial on pipeline candidate bimagrumab in obese patients with type II diabetes.

                                                Zacks Equity Research

                                                ARIAD: Acquisition by Takeda Bodes Well, Competition a Risk

                                                by Zacks Equity Research

                                                On Jan 13, we issued an updated report on ARIAD Pharmaceuticals, Inc. (ARIA).

                                                  Zacks Equity Research

                                                  Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit

                                                  by Zacks Equity Research

                                                  Eli Lilly and Company (LLY) announced that it has received a favorable ruling in a lawsuit against generic drugmaker Teva Pharmaceutical Industries Limited (TEVA) related to the infringement of a vitamin regimen patent for its cancer drug Alimta.